Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 110, Issue 1, 2008, Pages 60-64

  Wenzel, Lari ^a   Huang, Helen Q ^b   Cella, David ^c   Walker, Joan L ^d   Armstrong, Deborah K ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Abdominal discomfort; Measurement tool; Self assessment

Indexed keywords

CISPLATIN; PACLITAXEL;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CANCER PATIENT; CANCER THERAPY; CONFIDENCE INTERVAL; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; DOSE RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MORTALITY; NEUROTOXICITY; OVARY CANCER; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SELF EVALUATION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT DURATION; VALIDITY;

ABDOMINAL PAIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PAIN MEASUREMENT; QUESTIONNAIRES; RANDOM ALLOCATION;

EID: 45549087804     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.011     Document Type: Article

References (12)

1. Goff B.A., Mandel L.S., Melancon C.H., and Muntz H.G. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291 (2004) 2705-2712
2. Le T., Hopkins L., and Fung Kee Fung M. Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy. Int J Gynecol Cancer 15 (2005) 811-816
3. Vasey P.A., Jayson G.C., Gordon A., et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
4. Armstrong D., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer: a GOG study. N Engl J Med 354 (2006) 34-43
5. Wenzel L., Huang H., Armstrong D., et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally-debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 437-443
6. Walker J., Armstrong D.K., Huang H.Q., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 199 (2006) 27-32
7. http://ctep.cancer.gov/highlights/ovarian.html.
8. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M.A., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O). J Clin Oncol 19 (2001) 1809-1817
9. Cella D.F., Tulsky D.S., Gray G., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
10. Fayers P.M., and Machin D. Quality of life: assessment, analysis and interpretation (2000), John Wiley & Sons, Ltd
11. Sloan J., Cella D., and Hays R. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 58 (2005) 1217-1219
12. Hahn E., Cella D., Chassany O., Fairclough D., Wong G., Hays R., and and the Clinical Significance Consensus Meeting Group. Precision of health-related quality-of-life data compared to other clinical measures. Mayo Clin Proc 82 (2007) 1244-1254